PDF herunterladen
Semin Thromb Hemost 2004; 30(6): 649-655
DOI: 10.1055/s-2004-861507
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Controversies of Oral Antiplatelet Therapy in Acute Coronary Syndromes and Percutaneous Coronary Intervention

Vivek Rajagopal1 , 2 , Deepak L. Bhatt2
  • 1Cardiology Fellow, Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio
  • 2Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. Januar 2005 (online)

    Lizenzen und Reprints

ABSTRACT

Platelet activation is a pivotal event in the pathophysiology of acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI) and has a substantial impact on the outcomes in these settings. Aggressive implementation of antiplatelet therapy has significantly decreased adverse cardiovascular events, such as death, myocardial infarction (MI), stroke, and repeat revascularization. Although the widespread use of aspirin has contributed to this improvement, many patients continue to have a significant risk of recurrent events during the ensuing months to years. The advent of other antiplatelet agents, notably the thienopyridine clopidogrel bisulfate has heralded a new era of combined antiplatelet blockade, offering the hope of better outcomes. Recently, clinical trials have tested the use of dual oral antiplatelet blockade and have shown impressive results. Notably, the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial found that dual therapy with clopidogrel and aspirin in ACS reduced adverse cardiovascular events by 20% at 1 year (p < 0.001). The PCI-CURE substudy of CURE and the Clopidogrel for the Reduction of Events During Observation (CREDO) trial demonstrated that these benefits extend to patients undergoing both urgent and elective PCI. This article will explore the current role of and controversies in oral antiplatelet therapy after ACS and PCI.

KEYWORDS

Aspirin - clopidogrel - acute coronary syndromes - percutaneous coronary intervention

REFERENCES

  • 1 American Heart. Association .Heart and Stgroke Statistical Update. www.americanheart.org/presenter.jhtm/?identifier=1928. Accessed August 2003
    Google Scholar
  • 2 Bhatt D L, Topol E J. Scientific and therapeutic advances in antiplatelet therapy.  Nat Rev Drug Discov. 2003;  2 15-28
    CrossrefPubMedGoogle Scholar
  • 3 Mehta S R, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.  J Am Coll Cardiol. 2003;  41(4 Suppl S) 79S-88S
    CrossrefPubMedGoogle Scholar
  • 4 Ault K A, Cannon C P, Mitchell J et al.. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.  J Am Coll Cardiol. 1999;  33 634-639
    CrossrefPubMedGoogle Scholar
  • 5 Merlini P A, Bauer K A, Oltrona L et al.. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.  Circulation. 1994;  90 61-68
    PubMedGoogle Scholar
  • 6 Perretti M, Chiang N, La M et al.. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.  Nat Med. 2002;  8 1296-1302
    PubMedGoogle Scholar
  • 7 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 ( Second International Study of Infarct Survival) Collaborative Group.  Lancet. 1988;  2 349-360
    PubMedGoogle Scholar
  • 8 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
    CrossrefPubMedGoogle Scholar
  • 9 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
    CrossrefPubMedGoogle Scholar
  • 10 Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease.  Thromb Res. 2002;  108 37-42
    CrossrefPubMedGoogle Scholar
  • 11 MacDonald T M, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin.  Lancet. 2003;  361 573-574
    CrossrefPubMedGoogle Scholar
  • 12 Catella-Lawson F, Reilly M P, Kapoor S C et al.. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.  N Engl J Med. 2001;  345 1809-1817
    CrossrefPubMedGoogle Scholar
  • 13 Hollopeter G, Jantzen H M, Vincent D et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
    CrossrefPubMedGoogle Scholar
  • 14 Yusuf S, Zhao F, Mehta S R et al.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2001;  345 494-502
    CrossrefPubMedGoogle Scholar
  • 15 Budaj A, Yusuf S, Mehta S R et al.. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.  Circulation. 2002;  106 1622-1626
    CrossrefPubMedGoogle Scholar
  • 16 Yende S, Wunderink R G. Effect of clopidogrel on bleeding after coronary artery bypass surgery.  Crit Care Med. 2001;  29 2271-2275
    PubMedGoogle Scholar
  • 17 Hongo R H, Ley J, Dick S E, Yee R R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting.  J Am Coll Cardiol. 2002;  40 231-237
    PubMedGoogle Scholar
  • 18 Bhatt D L, Topol E J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.  JAMA. 2000;  284 1549-1558
    CrossrefPubMedGoogle Scholar
  • 19 Topol E J. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes.  J Am Coll Cardiol. 2003;  41(4 Suppl S) 123-129
    PubMedGoogle Scholar
  • 20 Lau W C, Waskell L A, Watkins P B et al.. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.  Circulation. 2003;  107 32-37
    CrossrefPubMedGoogle Scholar
  • 21 Serebruany V L, Steinhubl S R, Hennekens C H. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.  Circulation. 2003;  107 1568-1569
    CrossrefPubMedGoogle Scholar
  • 22 Serebruany V L, Malinin A I, Steinhubl S R, Callahan K P, Gurbel P A. Statins in General and Atorvastatin in Particular Do Not Affect Platelet Inhibition with Clopidogrel During Coronary Stenting. Presented at the 52nd Annual American College of Cardiology Scientific Sessions Chicago, IL; April 2, 2003
    Google Scholar
  • 23 Saw J, Steinhubl S R, Berger P B et al.. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.  Circulation. 2003;  108 921-924
    CrossrefPubMedGoogle Scholar
  • 24 Mitsios J V, Papathanasiou A I, Rodis F I et al.. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.  Circulation. 2004;  109 1335-1338
    CrossrefPubMedGoogle Scholar
  • 25 Kiemeneij F, Serruys P W, Macaya C et al.. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial.  J Am Coll Cardiol. 2001;  37 1598-1603
    CrossrefPubMedGoogle Scholar
  • 26 Serruys P W, van Hout B, Bonnier H et al.. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II).  Lancet. 1998;  352 673-681
    CrossrefPubMedGoogle Scholar
  • 27 Fischman D L, Leon M B, Baim D S et al.. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.  N Engl J Med. 1994;  331 496-501
    CrossrefPubMedGoogle Scholar
  • 28 Savage M P, Douglas Jr J S, Fischman D L et al.. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.  N Engl J Med. 1997;  337 740-747
    CrossrefPubMedGoogle Scholar
  • 29 Erbel R, Haude M, Hopp H W et al.. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group.  N Engl J Med. 1998;  339 1672-1678
    CrossrefPubMedGoogle Scholar
  • 30 Nath F C, Muller D W, Ellis S G et al.. Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome.  J Am Coll Cardiol. 1993;  21 622-627
    PubMedGoogle Scholar
  • 31 Schatz R A, Baim D S, Leon M et al.. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.  Circulation. 1991;  83 148-161
    PubMedGoogle Scholar
  • 32 Leon M B, Baim D S, Popma J J et al.. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.  N Engl J Med. 1998;  339 1665-1671
    CrossrefPubMedGoogle Scholar
  • 33 Hall P, Nakamura S, Maiello L et al.. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation.  Circulation. 1996;  93 215-222
    PubMedGoogle Scholar
  • 34 Schomig A, Neumann F J, Kastrati A et al.. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.  N Engl J Med. 1996;  334 1084-1089
    CrossrefPubMedGoogle Scholar
  • 35 Bertrand M E, Legrand V, Boland J et al.. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.  Circulation. 1998;  98 1597-1603
    PubMedGoogle Scholar
  • 36 Kastrati A, Schuhlen H, Hausleiter J et al.. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial.  Circulation. 1997;  96 462-467
    PubMedGoogle Scholar
  • 37 Urban P, Macaya C, Rupprecht H J et al.. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).  Circulation. 1998;  98 2126-2132
    PubMedGoogle Scholar
  • 38 Ito M K, Smith A R, Lee M L. Ticlopidine: a new platelet aggregation inhibitor.  Clin Pharm. 1992;  11 603-617
    PubMedGoogle Scholar
  • 39 Bhatt D L, Bertrand M E, Berger P B et al.. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.  J Am Coll Cardiol. 2002;  39 9-14
    PubMedGoogle Scholar
  • 40 Mueller C, Roskamm H, Neumann F J et al.. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.  J Am Coll Cardiol. 2003;  41 969-973
    CrossrefPubMedGoogle Scholar
  • 41 Mehta S R, Yusuf S, Peters R J et al.. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  Lancet. 2001;  358 527-533
    CrossrefPubMedGoogle Scholar
  • 42 Steinhubl S R, Berger P B, Mann III J T et al.. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.  JAMA. 2002;  288 2411-2420
    CrossrefPubMedGoogle Scholar
  • 43 Vivekananthan D P, Bhatt D L, Chew D P et al.. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.  Am J Cardiol. 2004;  94 358-360
    CrossrefPubMedGoogle Scholar
  • 44 Quinn M J, Bhatt D L, Zidar F et al.. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.  Am J Cardiol. 2004;  93 679-684
    CrossrefPubMedGoogle Scholar
  • 45 Cannon C P, McCabe C H, Wilcox R G et al.. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.  Circulation. 2000;  102 149-156
    PubMedGoogle Scholar
  • 46 Topol E J, Easton J D, Amarenco P et al.. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.  Am Heart J. 2000;  139 927-933
    CrossrefPubMedGoogle Scholar
  • 47 Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.  Lancet. 2000;  355 337-345
    CrossrefPubMedGoogle Scholar
  • 48 Second SYMPHONY Investigators . Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.  Circulation. 2001;  103 1727-1733
    PubMedGoogle Scholar
  • 49 O'Neill W W, Serruys P, Knudtson M et al.. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.  N Engl J Med. 2000;  342 1316-1324
    CrossrefPubMedGoogle Scholar
  • 50 Chew D P, Bhatt D L, Sapp S, Topol E J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.  Circulation. 2001;  103 201-206
    PubMedGoogle Scholar
  • 51 Kastrati A, Mehilli J, Schuhlen H et al.. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.  N Engl J Med. 2004;  350 232-238
    CrossrefPubMedGoogle Scholar
  • 52 Bhatt D L, Topol E J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.  Am Heart J. 2004;  148 263-268
    CrossrefPubMedGoogle Scholar

 Dr.
D. Bhatt

Cleveland Clinic Foundation, Department of Cardiovascular Medicine/F25

9500 Euclid Avenue, Cleveland, Ohio 44195

eMail: bhattd@ccf.org

      >